{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T02:15:16Z","timestamp":1794881716414,"version":"4.9.1"},"reference-count":62,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Cladribine, an oral prodrug, penetrates the blood\u2013brain barrier, impacting biomarkers of disease progression within the central nervous system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Describe disease activity in cladribine tablets (CladT)-treated people with highly active relapsing multiple sclerosis (pwRMS) using clinical outcomes and biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>MAGNIFY-MS was an open-label, single-arm, phase IV trial with four sub-studies. Participants were grouped by previous treatment (Tx); Tx-na\u00efve versus Tx-experienced; those with previous exposure to second-line therapies were excluded. This analysis describes cerebrospinal fluid (CSF) and optical coherence tomography (OCT) sub-studies. CSF sub-study participants were stratified by the number of oligoclonal bands (OCBs) at baseline (\u22652\/\u22654).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Logistic regression analysis is reported for no evidence of disease activity (NEDA)-3 and no evidence of progression or active disease (NEPAD) at Year (Y)1 and Y2, and annualized relapse rate (ARR) at Y2. Changes in intrathecal (OCBs, kappa free light chain [KFLC], immunoglobulin [Ig]G and IgM indices), OCT measures, and neuroaxonal degeneration (neurofilament light chain [NfL]) biomarkers are reported at baseline, month (M)12, and M24.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      MAGNIFY-MS included 270 pwRMS; 28 and 36 were included in the CSF and OCT sub-studies, respectively. In Y2, estimated rates of NEDA-3 were 64.1% overall and 69.1% in the Tx-na\u00efve group. The estimated rate of NEPAD overall was 60.2% in Y2. The estimated ARR was 0.09 from baseline to M24 (Tx-na\u00efve participants, 0.04). In participants with \u22652 OCBs at baseline (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200917), 76.5% had OCB reduction or disappearance at least once in the study. KFLC and IgG indices were reduced at M24 versus baseline. Sustained reductions were observed in median NfL, while IgG and IgM remained within normal ranges for most participants. Mean OCT measurements showed no retinal nerve fiber thinning.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>For CladT-treated pwRMS, disease activity and biomarkers of intrathecal inflammation and neuroaxonal damage were reduced versus baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov identifier, NCT03364036. Date registered: June 12, 2017. Date first patient enrolled: May 28, 2018.\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03364036\">https:\/\/clinicaltrials.gov\/study\/NCT03364036<\/jats:ext-link>\n                      . Extension study ClinicalTrials.gov Identifier: NCT04783935. Date registered: March 05, 2021. Date first patient enrolled: March 10, 2021.\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04783935\">https:\/\/clinicaltrials.gov\/study\/NCT04783935<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562864251351760","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T10:40:27Z","timestamp":1753958427000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9293-8893","authenticated-orcid":false,"given":"Klaus","family":"Schmierer","sequence":"first","affiliation":[{"name":"The Blizard Institute, Centre for Neuroscience, Surgery and Trauma, Faculty of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London E1 2AT, UK"},{"name":"Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[{"name":"Department of Neurology with Institute of Translational Neurology, University of M\u00fcnster, M\u00fcnster, Germany"},{"name":"Department of Neurology and Neurophysiology, Freiburg University, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands"},{"name":"Queen Square Institute of Neurology and Centre for Medical Image Computing, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-9918","authenticated-orcid":false,"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[{"name":"Department of Neurology\u2013Neuroimmunology, Centre d\u2019Esclerosi M\u00faltiple de Catalunya (Cemcat), Hospital Universitario Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2020-3126","authenticated-orcid":false,"given":"Anat","family":"Achiron","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Center, Sheba Academic Medical Center, Ramat Gan, Israel"},{"name":"Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8656-4250","authenticated-orcid":false,"given":"Tobias","family":"Derfuss","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hodgkinson","sequence":"additional","affiliation":[{"name":"Ingham Institute for Applied Medical Research, University of New South Wales Medicine and Liverpool Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Prat","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Leocani","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Vita-Salute San Raffaele, Milan, Italy"},{"name":"IRCCS San Raffaele Scientific Institute, Milan, Italy"},{"name":"Department of Neurorehabilitation Science, Casa di Cura Igea, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Sellebjerg","sequence":"additional","affiliation":[{"name":"Danish MS Center, Department of Neurology, Copenhagen University Hospital\u2014Rigshospitalet, Glostrup, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Vermersch","sequence":"additional","affiliation":[{"name":"Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hulin","family":"Jin","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sponton","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Chudecka","sequence":"additional","affiliation":[{"name":"Cytel Inc., Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Gardner","sequence":"additional","affiliation":[{"name":"EMD Serono Research &amp; Development Institute Inc., Billerica, MA, USA, an affiliate of Merck KGaA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"De Stefano","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2024.108249"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02588-7"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103931"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-34384-5"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001187"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.642384"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10081386"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-022-00925-2"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0288581"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11449-5"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.48.10.989"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/00045632231179618"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2017.05.026"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15500"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221134213"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1288169"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034823"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00095-8"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/93.3.491"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11817-9"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-282X1983000100003"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231205962"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199732020-00003"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.07.030"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.2147\/EB.S139417"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31827b1a1c"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10437-5"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/01616412.2020.1761174"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.10.040"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2008.06.008"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.110380"},{"key":"e_1_3_4_33_2","article-title":"Specific patterns of immune cell dynamics may explain the early onset and prolonged efficacy of cladribine tablets: a MAGNIFY-MS substudy","volume":"10","author":"Wiendl H","year":"2022","unstructured":"Wiendl H, Schmierer K, Hodgkinson S, et al. Specific patterns of immune cell dynamics may explain the early onset and prolonged efficacy of cladribine tablets: a MAGNIFY-MS substudy. Neurol Neuroimmunol Neuroinflamm 2022; 10: e200048.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.10.006"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-017-0812-y"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2014.06.010"},{"key":"e_1_3_4_37_2","first-page":"51","article-title":"Improved cognitive processing speed in patients treated with cladribine tablets for multiple sclerosis: MAGNIFY-MS 2-year findings (P070)","volume":"30","author":"Vermersch P","year":"2024","unstructured":"Vermersch P, Wiendl H, Barkhof F, et al. Improved cognitive processing speed in patients treated with cladribine tablets for multiple sclerosis: MAGNIFY-MS 2-year findings (P070). Mult Scler (Basingstoke, UK) 2024; 30: 51\u201352.","journal-title":"Mult Scler (Basingstoke, UK)"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519845844"},{"key":"e_1_3_4_39_2","article-title":"Kappa free light chain biomarkers are efficient for the diagnosis of multiple sclerosis: a large multicenter cohort study","volume":"10","author":"Levraut M","year":"2022","unstructured":"Levraut M, Laurent-Chabalier S, Ayrignac X, et al. Kappa free light chain biomarkers are efficient for the diagnosis of multiple sclerosis: a large multicenter cohort study. Neurol Neuroimmunol Neuroinflamm 2022; 10: e200049.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"e_1_3_4_41_2","first-page":"1011","article-title":"Cladribine controls multiple sclerosis by memory B cell depletion","volume":"23","author":"Ceronie B","year":"2017","unstructured":"Ceronie B, Zhifeng M, Ammoscato F, et al. Cladribine controls multiple sclerosis by memory B cell depletion. Mult Scler J 2017; 23: 1011\u20131012.","journal-title":"Mult Scler J"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00652-6"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.08.011"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1512189"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1177\/11795735211060118"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221099413"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004683"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518794308"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211057661"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.92.15_supplement.S56.008"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211010294"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211049392"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6775-0"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211012227"},{"key":"e_1_3_4_56_2","first-page":"38","volume":"25","author":"De Stefano N","year":"2023","unstructured":"De Stefano N, Achiron A, Barkhof F, et al. DMT44\u2014efficacy in clinical and MRI outcomes with cladribine tablets treatment in highly active relapsing multiple sclerosis (MAGNIFY-MS). Poster presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, Aurora, CO, USA, Int J MS Care 2023; 25: 38\u201339.","journal-title":"DMT44\u2014efficacy in clinical and MRI outcomes with cladribine tablets treatment in highly active relapsing multiple sclerosis (MAGNIFY-MS). Poster presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, Aurora, CO, USA, Int J MS Care"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909494"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000561"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2023.107885"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00364-6"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241233044"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-020-00187-3"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251351760","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864251351760","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251351760","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:05:49Z","timestamp":1767675949000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864251351760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":62,"alternative-id":["10.1177\/17562864251351760"],"URL":"https:\/\/doi.org\/10.1177\/17562864251351760","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"article-number":"17562864251351760"}}